Abstract: This disclosure provides crystalline, salt forms of a KRAS inhibitor, pharmaceutical compositions comprising a KRAS inhibitor, and efficient and scalable processes for preparing a KRAS inhibitor.

Abstract: The present application discloses a method for constructing a high-conductivity fracture of carbonate reservoir stimulation, and belongs to the field of oil and gas field stimulation. The method includes: S1. determining a lithology of a target layer; S2. preliminarily selecting a rock strengthening agent for in-situ modification of the fracture wall surfaces; S3. performing an experiment on in-situ modification of the fracture wall surfaces with the rock strengthening agent under a reservoir environment; S4. selecting the rock strengthening agent based on the experimental results; S5. constructing a mathematical model relating rock embedment strength to factors such as the rock strengthening agent; S6. constructing a mathematical model relating fracture conductivity to factors such as the rock embedment strength of the fracture wall surfaces; and S7. inversely designing parameters such as the rock strengthening agent based on the fracture conductivity required in the reservoir stimulation.

Abstract: The present application discloses a method for constructing a high-conductivity fracture of carbonate reservoir stimulation, and belongs to the field of oil and gas field stimulation. The method includes: S1. determining a lithology of a target layer, S2. preliminarily selecting a rock strengthening agent for in-situ modification of the fracture wall surfaces; S3. performing an experiment on in-situ modification of the fracture wall surfaces with the rock strengthening agent under a reservoir environment; S4. selecting the rock strengthening agent based on the experimental results; S5. constructing a mathematical model relating rock embedment strength to factors such as the rock strengthening agent; S6. constructing a mathematical model relating fracture conductivity to factors such as the rock embedment strength of the fracture wall surfaces; and S7. inversely designing parameters such as the rock strengthening agent based on the fracture conductivity required in the reservoir stimulation.

Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

Abstract: This invention relates to topical skin formulations comprising a pharmaceutically acceptable salt of ruxolitinib, and use in the treatment of skin disorders.

Abstract: The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.

Abstract: The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.

Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

Abstract: This disclosure provides efficient and scalable processes for preparing a KRAS inhibitor.

Abstract: The present invention is related to processes for preparing itacitinib, or a salt thereof, and related synthetic intermediates related thereto.

Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.

Abstract: The present disclosure is related to solid forms of ruxolitinib di-hydrate and ruxolitinib free base, process of preparing the same, and compositions comprising the same.

Abstract: Disclosed is an infinite-stage fracturing sliding sleeve. The infinite-stage fracturing sliding sleeve includes an outer cylinder, an inner cylinder, a sliding cylinder, an elastic element and a counting mechanism, wherein the inner cylinder closes a fracturing hole on the outer cylinder, and a lower end of the sliding cylinder is provided with an elastic claw. When the number of fracturing balls is less than a preset value, the elastic claw of the sliding cylinder moves in a reduced diameter section and an expanded diameter section in the outer cylinder. After the fracturing sliding sleeve is adopted, the fracturing sliding sleeves of all stages may be driven to open by fracturing balls of the same size, and there is no size difference between the fracturing sliding sleeves of all stages, so that the number of fracturing stages is not limited.

Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.

Abstract: The present disclosure is related to solid forms of ruxolitinib di-hydrate and ruxolitinib free base, process of preparing the same, and compositions comprising the same.

Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.

Abstract: The present disclosure is related to processes for preparing baricitinib, salts thereof, and related synthetic intermediate compounds and salts thereof.

Abstract: The present invention provides an asphaltene dispersion stabilizer and a preparation method therefor, and relates to the technical field of oilfield additives. The asphaltene dispersion stabilizer is prepared by the following method: taking iminodisuccinic acid or salt thereof, and performing Michael addition reaction on the iminodisuccinic acid or the salt thereof and unsaturated sulfonate to prepare a first intermediate; taking the first intermediate, and performing amidation reaction on the first intermediate and a first monomer under the action of a catalyst to obtain a second intermediate; and preparing a dendrimer by taking the second intermediate as a core and taking a second monomer and a third monomer as raw materials, wherein the dendrimer is the asphaltene dispersion stabilizer, and the generation number of the dendrimer is 0.5 generations, 1.5 generations or 2.5 generations. The asphaltene dispersion stabilizer of the present invention has a good dispersion stabilization effect on asphaltene.

Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

Abstract: The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.